Zenas BioPharma company raises $118M

Zenas BioPharma, a biopharmaceutical company specializing in the development of autoimmune disease therapeutics, has raised $118 million in series B financing.

The proceeds from the round will be used to develop and commercialize Obexelimab, the company's leading drug candidate used in the treatment of IgG4-related disease, according to a Nov. 7 Zenas news release provided to Becker's

The company plans to launch a phase 3 registration trial for Obexelimab in late 2022 and launch the company's other autoimmune disease programs in 2023, the release said.

Enavate Sciences led the funding round. 

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars